ATC Group: L03AX22 Leniolisib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L03AX22 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L03 Immunostimulants
3 L03A Immunostimulants
4 L03AX Other immunostimulants
5 L03AX22

Active ingredients in L03AX22

Active Ingredient Description
Leniolisib

Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets.

Related product monographs

Title Information Source Document Type  
JOENJA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.